What is MiMedx Group's stock-based comp?

MiMedx Group (MDXG) reported stock-based comp of -$1.7M in Q1 2026.

How has MiMedx Group's stock-based comp changed year-over-year?

MiMedx Group's stock-based comp decreased by 139.8% year-over-year, from $4.26M to -$1.7M.

What is the long-term trend for MiMedx Group's stock-based comp?

Over 4 years (2021 to 2025), MiMedx Group's stock-based comp has grown at a 3.7% compound annual growth rate (CAGR), from $14.16M to $16.4M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

MiMedx Group MDXG Stock-Based Comp

Stock-Based Comp at other companies

IAR

Integra LifeSciencesIART

$5.17M+176%

Organogenesis Holdings Inc.ORGO

$3.64M+8.0%

ArtivionAORT

$8.41M+4.6%

SolventumSOLV

$51M+4.1%

VericelVCEL

$11.29M-1.8%

EnovisENOV

$8.75M+18.1%

Other financials

Income statement

See full

Revenue$59.0M-33.1%

Gross profit$41.6M-41.9%

Operating income-$16.0M-295%

Net income-$10.9M-255%

EPS (diluted)-$0.07-240%

Balance sheet

See full

Cash & equivalents$159.8M+50.1%

Total debt$17.6M-5.7%

Total equity$242.9M+19.8%

Total assets$308.7M+14.1%

Cash flow

See full

Operating cash flow$1.9M-64.5%

CapEx$570.0K+51.2%

Free cash flow$1.3M-73.4%

Valuation

See full

Market cap$567.48M-33.9%

Enterprise value$425.3M-44.8%

P/E18.5×-2.9×

P/S1.5×-1.0×

Profitability

See full

Gross margin81%-0.9pp

Operating margin10.2%-5.1pp

Net margin7.9%-3.5pp

FCF margin17.8%-0.5pp

Returns & leverage

See full

Return on equity13.8%-8.6pp

Debt / equity0.1×0.0×

Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MiMedx Group's stock-based comp?: MiMedx Group (MDXG) reported stock-based comp of -$1.7M in Q1 2026.
How has MiMedx Group's stock-based comp changed year-over-year?: MiMedx Group's stock-based comp decreased by 139.8% year-over-year, from $4.26M to -$1.7M.
What is the long-term trend for MiMedx Group's stock-based comp?: Over 4 years (2021 to 2025), MiMedx Group's stock-based comp has grown at a 3.7% compound annual growth rate (CAGR), from $14.16M to $16.4M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.